NASDAQ:MBIO - Mustang Bio Stock Price, Price Target & More

$8.86 -0.40 (-4.32 %)
(As of 04/26/2018 03:22 AM ET)
Previous Close$9.26
Today's Range$8.78 - $9.38
52-Week Range$8.06 - $13.35
Volume66,527 shs
Average Volume86,060 shs
Market Capitalization$261.75 million
P/E Ratio-11.85
Dividend YieldN/A
BetaN/A

About Mustang Bio (NASDAQ:MBIO)

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T (CAR T) cell technology. The company's CAR T product candidates include MB-101, a IL13Ra2 CAR T cell program which is in Phase I clinical study for glioblastoma; and MB-102, a CD123 CAR T cell program to treat acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm; and MB-106, a CD20 CAR T cell program that is in Phase I clinical study for the treatment of B cell non-Hodgkin lymphoma. It also develops MB-104, a CS1 CAR T, which is in Preclinical study for multiple myeloma and light chain amyloidosisy; MB-103, a human epidermal growth factor receptor 2 CAR T that is in Preclinical study to treat glioblastoma multiforme and metastatic breast cancer to brain; and MB-105, a prostate stem-cell antigen CAR T for prostate and pancreatic cancers. The company has a partnership agreement with the City of Hope National Medical Center and Fred Hutchinson Cancer Research Center to develop proprietary CAR T therapies across various cancers. It also holds a license agreement with Harvard University; and a research collaboration agreement with Beth Israel Deaconess Medical Center for the development of CRISPR/Cas9-enhanced CAR T therapies for the treatment of cancer. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.

Receive MBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBIO
CUSIPN/A
Phone781-652-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio17.00%
Quick Ratio17.00%

Price-To-Earnings

Trailing P/E Ratio-11.85
Forward P/E Ratio-8.95
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.27 per share
Price / Book3.90

Profitability

EPS (Most Recent Fiscal Year)($0.75)
Net Income$-31,280,000.00
Net MarginsN/A
Return on Equity-31.64%
Return on Assets-30.28%

Miscellaneous

Employees6
Outstanding Shares27,100,000

How to Become a New Pot Stock Millionaire

Mustang Bio (NASDAQ:MBIO) Frequently Asked Questions

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

How were Mustang Bio's earnings last quarter?

Mustang Bio (NASDAQ:MBIO) posted its earnings results on Thursday, March, 29th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.02. View Mustang Bio's Earnings History.

What price target have analysts set for MBIO?

2 brokers have issued 1 year price objectives for Mustang Bio's stock. Their predictions range from $18.00 to $18.00. On average, they expect Mustang Bio's stock price to reach $18.00 in the next twelve months. View Analyst Ratings for Mustang Bio.

Who are some of Mustang Bio's key competitors?

Who are Mustang Bio's key executives?

Mustang Bio's management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman (Age 52)
  • Dr. Manuel Litchman M.D., Pres, Chief Exec. Officer & Director (Age 64)
  • Mr. Brian K. Achenbach, Interim CFO, VP of Fin. & Corp. Controller (Age 53)
  • Dr. Knut Niss, Chief Technology Officer
  • Dr. Sadik Kassim, Chief Scientific Officer

Has Mustang Bio been receiving favorable news coverage?

Media coverage about MBIO stock has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Mustang Bio earned a media sentiment score of 0.25 on Accern's scale. They also gave press coverage about the company an impact score of 46.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Mustang Bio?

Shares of MBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $8.86.

How big of a company is Mustang Bio?

Mustang Bio has a market capitalization of $261.75 million. The company earns $-31,280,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Mustang Bio employs 6 workers across the globe.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Mustang Bio (MBIO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  23 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  38
MarketBeat's community ratings are surveys of what our community members think about Mustang Bio and other stocks. Vote "Outperform" if you believe MBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mustang Bio (NASDAQ:MBIO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Mustang Bio in the last 12 months. Their average twelve-month price target is $18.00, suggesting that the stock has a possible upside of 103.16%. The high price target for MBIO is $18.00 and the low price target for MBIO is $18.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $18.00$18.00$18.00N/A
Price Target Upside: 103.16% upside64.68% upside64.68% upsideN/A

Mustang Bio (NASDAQ:MBIO) Consensus Price Target History

Price Target History for Mustang Bio (NASDAQ:MBIO)

Mustang Bio (NASDAQ:MBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2017CIBCInitiated CoverageOutperform -> Outperform$18.00MediumView Rating Details
12/20/2017OppenheimerInitiated CoverageOutperform$18.00MediumView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Mustang Bio (NASDAQ:MBIO) Earnings History and Estimates Chart

Earnings by Quarter for Mustang Bio (NASDAQ:MBIO)

Mustang Bio (NASDAQ:MBIO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.00)
2019 EPS Consensus Estimate: ($1.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.24)($0.24)($0.24)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.28)($0.28)($0.28)
Q1 20191($0.28)($0.28)($0.28)
Q2 20191($0.28)($0.28)($0.28)
Q3 20191($0.26)($0.26)($0.26)
Q4 20191($0.28)($0.28)($0.28)

Mustang Bio (NASDAQ MBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018Q4 2017($0.24)($0.22)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mustang Bio (NASDAQ:MBIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mustang Bio (NASDAQ MBIO) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 2.83%
Insider Trading History for Mustang Bio (NASDAQ:MBIO)

Mustang Bio (NASDAQ MBIO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Mustang Bio (NASDAQ MBIO) News Headlines

Source:
DateHeadline
Mustang Bio (MBIO) Raised to "Buy" at Zacks Investment ResearchMustang Bio (MBIO) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 11 at 7:56 AM
Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy?Mustang Bio (MBIO) Sees Hammer Chart Pattern: Time to Buy?
www.zacks.com - April 6 at 10:07 AM
Zacks Investment Research Downgrades Mustang Bio (MBIO) to HoldZacks Investment Research Downgrades Mustang Bio (MBIO) to Hold
www.americanbankingnews.com - April 6 at 9:37 AM
Mustang Bio (MBIO) Stock Rating Upgraded by Zacks Investment ResearchMustang Bio (MBIO) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 12:03 PM
Mustang Bio to Present at Biotech Innovations ConferenceMustang Bio to Present at Biotech Innovations Conference
finance.yahoo.com - April 4 at 10:27 AM
Oppenheimer Comments on Mustang Bio Incs Q1 2018 Earnings (MBIO)Oppenheimer Comments on Mustang Bio Inc's Q1 2018 Earnings (MBIO)
www.americanbankingnews.com - April 4 at 7:33 AM
Mustang Bio Inc (MBIO) Forecasted to Earn FY2022 Earnings of $0.73 Per ShareMustang Bio Inc (MBIO) Forecasted to Earn FY2022 Earnings of $0.73 Per Share
www.americanbankingnews.com - April 3 at 7:46 AM
Mustang Bio (MBIO) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowMustang Bio (MBIO) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 3:27 PM
Mustang Bio Announces Key Leadership AppointmentsMustang Bio Announces Key Leadership Appointments
finance.yahoo.com - March 15 at 10:02 AM
Mustang Bio to Present at the 255th American Chemical Society National Meeting & ExpositionMustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition
finance.yahoo.com - March 12 at 8:35 AM
Mustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor ConferenceMustang Bio to Participate in Immuno-Oncology Panel at BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 5:22 PM
Research Analysts Issue Forecasts for Mustang Bio Incs FY2017 Earnings (MBIO)Research Analysts Issue Forecasts for Mustang Bio Inc's FY2017 Earnings (MBIO)
www.americanbankingnews.com - December 25 at 1:58 AM
CIBC Initiates Coverage on Mustang Bio (MBIO)CIBC Initiates Coverage on Mustang Bio (MBIO)
www.americanbankingnews.com - December 21 at 5:12 PM
Mustang Bio (MBIO) Research Coverage Started at OppenheimerMustang Bio (MBIO) Research Coverage Started at Oppenheimer
www.americanbankingnews.com - December 20 at 7:20 PM

SEC Filings

Mustang Bio (NASDAQ:MBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mustang Bio (NASDAQ:MBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mustang Bio (NASDAQ MBIO) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.